Regeneron Starts Human Clinical Trials Of Covid-19 Antibody Cocktail

Regeneron Pharmaceuticals, Inc (REGN) said Thursday it started the first human clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19.

Don't Miss Our Christmas Offers:

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, individuals that are at high-risk of exposure, such as healthcare workers or first responders, and people with close exposure to a COVID-19 patient. The placebo-controlled trials will be conducted at multiple sites.

“We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral ‘escape,’ a critical precaution in the midst of an ongoing global pandemic,” said George D. Yancopoulos, Co-Founder and Chief Scientific Officer of Regeneron. “REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner than a vaccine.”

Yancopoulos added that the antibody cocktail approach would also be useful for elderly and immuno-compromised patients, who often do not respond well to vaccines.

REGN-COV2’s preclinical development and manufacturing has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA).

Shares in Regeneron have surged 62% so far this year. The stock declined 1.7% to $596.18 in early afternoon trading.

Five-star analyst Alethia Young at Cantor Fitzgerald this month raised the stock’s price target to $624 (3.7% upside potential) from $400 and maintained a Hold rating, saying its drug pipeline faces stiff competition in the generics market.

“Potential upside may come from a sustainable commercial COVID-19 franchise, where studies should begin soon,” Young wrote in a note to investors.

What does the rest of the Street have to say? The 20 analysts are divided evenly between 10 Buy and 10 Hold ratings adding up to a Moderate Buy consensus. In view of the stock’s recent rally, the analysts’ $573.26 average price target is less optimistic than Young’s indicating a mere 3.5% downside potential in the coming 12 months. (See Regeneron stock analysis on TipRanks).